Vilazodone Hydrochloride Tablet, Film Coated
Product Images NDC 51407-917

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Vilazodone Hydrochloride (NDC 51407-917). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-915-30lb (Vilazodone HCl 10 mg)

Vilazodone Hydrochloride 10 mg film-coated tablets label featuring the product name, dosage strength, and quantity of 30 tablets. The label includes NDC 51407-915-30, barcode, storage instructions, and dispensing information. Marketed by GSMS, Incorporated, Camarillo, CA.*

FDA Label Image

51407-916-30lb (Vilazodone HCl 20 mg)

Label for Vilazodone Hydrochloride 20 mg film-coated tablets by Golden State Medical Supply, Inc. The label shows 30 tablets per container and includes the NDC 51407-916-30. It contains directions for pharmacists to dispense a medication guide and storage instructions at 20° to 25°C. The label also includes a barcode and mentions child-resistant packaging.*

FDA Label Image

51407-917-30lb (Vilazodone HCl 40 mg)

Label for Vilazodone Hydrochloride film-coated tablets, 40 mg strength, in a package of 30 tablets. The label includes the NDC 51407-917-30, directions for pharmacists to dispense the medication guide, storage instructions to keep at 20° to 25°C, and child-resistant container requirements. Marketed by GSMS, Incorporated, Camarillo, CA.*

FDA Label Image

Formula (Image 1)

Chemical structure of Vilazodone Hydrochloride depicted in a molecular diagram showing its atomic arrangement and bonds, including the hydrochloride component.*

FDA Label Image

Fig1 (Image 2)

A forest plot chart depicting pharmacokinetic changes (Cmax and AUC) of Vilazodone Hydrochloride when co-administered with ethanol, CYP3A4 inhibitors (ketoconazole), CYP3A4 inducers (carbamazepine), and proton pump inhibitors (pantoprazole). The horizontal axis shows fold change relative to reference, with points and 90% confidence intervals representing measured changes for each substance.*

FDA Label Image

Fig2 (Image 3)

A forest plot chart displaying fold change and 90% confidence intervals for pharmacokinetic parameters of various CYP and P-gp substrates relative to a reference. The chart lists substrates including Nifedipine, Caffeine, Debrisquone, Flurbiprofen, Mephenytoin, and Digoxin, with corresponding pharmacokinetic measures such as AUCp, CRmp, URmp, CLm, Um, Cmax, and AUC, showing changes in exposure levels relative to a reference value of 1.0.*

FDA Label Image

Fig3 (Image 4)

A fold change chart showing pharmacokinetic data (Cmax and AUC) with 90% confidence intervals for Vilazodone Hydrochloride in different populations, including age greater than 65 years, females, and varying degrees of renal and hepatic impairment. The x-axis represents change relative to reference, ranging from 0.5 to 2.0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.